CI

At a glance

ClinicalIndex Comparison Record
Phase 3Active· 397 enrolled
Drug / intervention
Radiation therapy - 3 weeks +1 moreradiation
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT04175210
NCT04175210Phase 3Active

Prospective Randomized Study of Accelerated Radiation Therapy (PRART) : A Non-Inferiority Trial to Compare Breast Cosmesis and Local Control After Concomitant Boost Breast Radiotherapy With Fifteen Fractions in Three Weeks (Arm 1, Standard) Versus Ten Fractions in Two Weeks (Arm 2, Experimental)

Weill Medical College of Cornell University·interventional·Posted Nov 22, 2019·Updated May 7, 2026

In Brief

A Phase 3 clinical trial evaluating Radiation therapy - 3 weeks and Radiation therapy - 2 weeks for Breast Cancer. Active but no longer recruiting, targeting 397 participants across 3 sites.

Detailed Summary

Patients with Stage 0 ductal carcinoma in situ (Tis (DCIS), Stage T1-T2, lymph node negative(N0) breast cancers will be randomized to receive whole breast radiotherapy with a concomitant boost to the tumor bed over 15 fractions (Arm 1, standard) versus 10 fractions (Arm 2, experimental).

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsBreast Cancer
CountriesUnited States
Collaborators--

Timeline

Phase 3Active
20202021202220232024202520262027202820292030
First PostedNov 22, 2019
Enrollment StartNov 21, 2019
Primary CompletionJul 15, 2025
Study CompletionJun 30, 2030
TodayJul 2, 2026
Enrollment to primary: 5.6 yearsPosted 6.6 years ago

Interventions

Radiation therapy - 3 weeksradiation

Patients randomized to ARM 1 will receive whole breast radiotherapy of 4050cGY and a concomitant boost to the tumor bed of 4800cGY in 15 fractions

Radiation therapy - 2 weeksradiation

Patients randomized to ARM 2 will receive whole breast radiotherapy of 3200cGY and a concomitant boost to the tumor bed of 4200cGY in 10 fractions.